Literature DB >> 20109338

C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines.

Pei-Yu Huang1, Ming-Huang Hong, Xing Zhang, Hai-Qiang Mai, Dong-Hua Luo, Li Zhang.   

Abstract

BACKGROUND AND
OBJECTIVE: We previously reported that C-KIT overexpression and mutation exist in biopsy samples of nasopharyngeal carcinoma (NPC). Yet whether Imatinib had an inhibitory effect on the proliferation of NPC in vitro was still unknown. So, this study examined whether sensitivities to Imatinib of other cell lines are different and whether C-KIT expression and mutations exist, to analyze the correlations between them.
METHODS: The expression of C-KIT in NPC cell lines, including CNE-1, CNE-2, Hone-1, C-666, SUNE-1, 5-8F, and nasopharyngeal epithelial (NPE) cell line NP-69, were detected by Western blot. Direct sequencing of polymerase chain reaction (PCR) products was performed to analyze the sequences of C-KIT from the above-mentioned cell lines. Inhibitory effects on proliferation by Imatinib on these cell lines were determined by CCK-8 assay. Pearson product moment correlation and t test were used to analyze the correlation betweeen C-KIT overexpression, C-KIT gene mutation, and the inhibitory effect of Imatinib.
RESULTS: Compared with NPE cell line NP-69, NPC cell lines CNE-1, CNE-2, Hone-1, C-666, SUNE-1, and 5-8F had significantly higher levels of C-KIT expression. Heterozygous IVS17+78T>C were found in CNE-1, CNE-2, Hone-1, and NP-69 cell lines, homozygous IVS17+78T>C was found in C-666, and no mutation was found in SUNE-1 or 5-8F. Imatinib had a dose-dependent inhibitory effect on proliferation for CNE-1, CNE-2, Hone-1, C-666, SUNE-1, and 5-8F. No significant correlation between the inhibitory effects of Imatinib, C-KIT overexpression, or C-KIT mutation was found.
CONCLUSION: C-KIT overexpression and intron mutation were found in NPC cell lines and Imatinib had a dose-dependent inhibitory effect on proliferation for NPC cell lines, yet no significant correlation between C-KIT overexpression, C-KIT mutation, or the inhibitory effect of Imatinib was found.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109338     DOI: 10.5732/cjc.009.10411

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


  7 in total

1.  Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.

Authors:  Feng Jiang; Wei Hu; Bicheng Zhang; Jing Xu; Yongjie Shui; Xiaofeng Zhou; Xiaoqiu Ren; Xiaozhong Chen; Li Shen; Qichun Wei
Journal:  Biomed Rep       Date:  2016-09-12

2.  Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.

Authors:  Jian-Wei Zhang; Tao Qin; Shao-Dong Hong; Jing Zhang; Wen-Feng Fang; Yuan-Yuan Zhao; Yun-Peng Yang; Cong Xue; Yan Huang; Hong-Yuan Zhao; Yu-Xiang Ma; Zhi-Huang Hu; Pei-Yu Huang; Li Zhang
Journal:  Chin J Cancer       Date:  2015-04-08

3.  Oncogene mutational profile in nasopharyngeal carcinoma.

Authors:  Zi-Chen Zhang; Sha Fu; Fang Wang; Hai-Yun Wang; Yi-Xin Zeng; Jian-Yong Shao
Journal:  Onco Targets Ther       Date:  2014-03-20       Impact factor: 4.147

4.  Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation.

Authors:  Sathid Aimjongjun; Zimam Mahmud; Yannasittha Jiramongkol; Glowi Alasiri; Shang Yao; Ernesto Yagüe; Tavan Janvilisri; Eric W-F Lam
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

Review 5.  Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.

Authors:  Xue Liu; Yayan Deng; Yujuan Huang; Jiaxiang Ye; Sifang Xie; Qian He; Yong Chen; Yan Lin; Rong Liang; Jiazhang Wei; Yongqiang Li; Jinyan Zhang
Journal:  Curr Oncol       Date:  2022-08-23       Impact factor: 3.109

6.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.

Authors:  Fen Yang; Xiao-Jun Qian; Wei Qin; Rong Deng; Xiao-Qi Wu; Juan Qin; Gong-Kan Feng; Xiao-Feng Zhu
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

7.  Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.

Authors:  Qiuyan Chen; Linquan Tang; Na Liu; Feng Han; Ling Guo; Shanshan Guo; Jianwei Wang; Huai Liu; Yanfang Ye; Lu Zhang; Liting Liu; Pan Wang; Yingqin Li; Qingmei He; Xiaoqun Yang; Qingnan Tang; Yang Li; YuJing Liang; XueSong Sun; Chuanmiao Xie; Yunxian Mo; Ying Guo; Rui Sun; Haoyuan Mo; Kajia Cao; Xiang Guo; Musheng Zeng; Haiqiang Mai; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2018-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.